Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of LZM012 versus secukinumab in moderate to severe chronic plaque psoriasis
CTR20231931Phase 3Completed
- Sponsor
- Lichen Biotech
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lzm012, secukinumab in psoriasis, sponsored by Lichen Biotech. Started Aug 2023; status: completed.
02
Drugs
lzm012secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20231931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231931.